- Home
- LENZ vs RNA Comparison
LENZ vs RNA Comparison
Compare LENZ & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LENZ | RNA |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.8M | 211.6M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LENZ | RNA |
|---|---|---|
| Price | $5.90 | $13.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | $44.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 701.8K | 213.5K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | N/A |
| Revenue This Year | $50.42 | $88.12 |
| Revenue Next Year | $197.16 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.23 | $11.40 |
| 52 Week High | $50.19 | $73.06 |
Technical Indicators
Market Signals| Indicator | LENZ | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 59.91 |
| Support Level | $5.23 | $12.56 |
| Resistance Level | $10.42 | $14.05 |
| Average True Range (ATR) | 0.42 | 0.47 |
| MACD | 0.05 | 0.18 |
| Stochastic Oscillator | 35.43 | 90.85 |
Price Performance
Historical ComparisonAbout LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.